Ladenburg Thalmann: Maintaining the Aileron Therapeutics (ALRN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $9.00 to $19.00.
Aileron Therapeutics Analyst Ratings
Ladenburg Thalmann Upgrades Aileron Therapeutics to Buy, Announces $9 Price Target
Aileron Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aileron Therapeutics (ALRN) and OrthoPediatrics (KIDS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Henry Schein (HSIC), Aileron Therapeutics (ALRN) and EFFECTOR Therapeutics (EFTR)
No Data